Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

• Status: Completed
• Trial end date: 2019-10-12
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this safety long-term follow-up study is to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oyster Point Pharma, Inc.
• Treatments: Varenicline

Criteria

Inclusion Criteria:

1. Have been enrolled in the OPP-002 study

2. Have received at least one dose of the study drug/placebo in OPP-002 study

3. Completed the OPP-002 study to Visit 5

4. Have provided verbal and written informed consent

Exclusion Criteria:

1. Have discontinued prior to Visit 5 in the OPP-002 study.